Construction of a predictive model and prognosis of left ventricular systolic dysfunction in patients with sepsis based on the diagnosis using left ventricular global longitudinal strain

Jiangquan Yu1,2,*, Ruiqiang Zheng2, Penglei Yang3 and Daxin Wang1,2*

Abstract

Background: Cardiac dysfunction, a common complication of sepsis, is associated with increased mortality. However, its risk factors are poorly understood, and a predictive model might help in the management of cardiac dysfunction.

Methods: A monocentric prospective study of patients with sepsis was performed. Left ventricular global longitudinal strain (LV GLS) was measured using echocardiography within 72 h of the patients diagnosed with sepsis, and the patients were categorized into two groups: LV GLS > -17%, left ventricular systolic dysfunction group (LVSD group); and LV GLS ≤ -17%, non-left ventricular systolic dysfunction group (Non-LVSD group). The baseline characteristics and prognosis of the two groups were analyzed. Based on the results of the multivariate logistic regression analysis, a predictive model of LVSD was established and a nomogram was drawn.

Results: Fifty-one left ventricular systolic dysfunction in patients with sepsis and 73 non-LVSD sepsis patients were included. Prognostic analysis showed that patients with LVSD had higher ICU mortality, in-hospital mortality, the incidence of atrial fibrillation (P < 0.05), and risk of death (HR = 3.104, 95% CI = 1.617–5.957, P < 0.001) compared to patients with non-LVSD. There were no significant differences in the rate of tracheal intubation, the incidence of acute kidney injury (AKI), the proportion of continuous renal replacement therapy (CRRT), length of ICU stay, and length of hospital stay between the 2 groups (P > 0.05). High sensitive troponin I (Hs-TnI) ≥ 0.131 ng/ml, procalcitonin (PCT) ≥ 40 ng/ml, lactate (Lac) ≥ 4.2 mmol/L, and N-terminal pro-brain natriuretic peptide (NT-proBNP) ≥ 3270 pg/ml were found to be the best cut-off values for the prediction of LVSD.

Conclusion: Sepsis patients with left ventricular systolic dysfunction had a higher risk of death and atrial fibrillation. Hs-TnI, PCT, Lac, and NT-proBNP were independent risk factors of LVSD, and the LVSD predictive model constructed using these factors showed good diagnostic performance.

Trial registration: Chinese Clinical Trial Registry No: ChiCTR2000032128. Registered on 20 April 2020, http://www.chictr.org.cn/showproj.aspx?proj=52531.

*Correspondence: 18051060659@163.com

1 Medical College, Yangzhou University, Yangzhou 225001, China

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Keywords: Sepsis, Left ventricular systolic dysfunction, Echocardiography, Predictive model, Left ventricle global longitudinal strain

Background
Sepsis patients complicated with cardiac dysfunction have been recognized for more than 40 years [1, 2]. The mortality due to sepsis related to cardiac dysfunction (SRCD) is high, its pathogenesis is not fully understood, and the diagnostic criteria are not yet defined. Early detection of SRCD is important for prognosis and guiding treatment [3]. In previous studies, left ventricular ejection fraction (LVEF) < 50% was used as a criterion to diagnose left ventricular systolic dysfunction in patients with sepsis [4]. However, EF is significantly affected by afterload. Studies have shown that left ventricular global longitudinal strain (LV GLS) is more sensitive than LVEF in the diagnosis of left ventricular systolic dysfunction in patients with sepsis and has a higher correlation with prognosis [5]. Few predictive models of left ventricular systolic dysfunction in patients with sepsis have been proposed. In the current study, LV GLS was used to diagnose left ventricular systolic dysfunction. Using a case-control study, the related risk factors were explored to understand the prognosis of patients with left ventricular systolic dysfunction and establish a predictive model. With the current study, a portion of heart failure patients with preserved ejection fraction might be identified. Also, the difference in the prognosis between patients with left ventricular systolic dysfunction and patients with normal cardiac function was analyzed, and we hope to provide more clinical evidence for left ventricular systolic dysfunction in patients with sepsis.

Materials and methods
Study design and patients
This monocentric prospective study was carried out in the Northern Jiangsu People's Hospital, China, between April 2020 and January 2021. Inclusion criteria: (1) adult patients > 18 years old; (2) meeting the criteria for sepsis-3 from the Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 [6]. Exclusion criteria: (1) severe arrhythmias (such as persistent or permanent atrial fibrillation); (2) pregnancy; (3) congenital heart disease; (4) moderate-to-severe valvular disease or history of valve replacement; (5) acute myocardial infarction or myocarditis, chronic heart failure; (6) terminal stage of cancer; (7) patients diagnosed with sepsis in other wards for more than 24 h before being transferred to the center; (8) simultaneous participation in other studies. Elimination criteria: patients who died, whose echocardiography was not performed within 72 h, and whose echocardiogram images were unclear or could not be used to measure LV GLS.

Methods
Based on the previous results [7, 8], LV GLS > -17% was defined as left ventricular systolic dysfunction in the current study. LV GLS was measured using 2D spot echocardiography (GE Healthcare, Marlborough, MA, USA) with a frequency of 1.7–3.4 MHz, and M5s probe within 72 h of the patients diagnosed with sepsis. Chest electrocardiogram was performed in the left lateral decubitus position to obtain left ventricular end-systolic diameter, left ventricular end-diastolic volume, and left ventricular ejection fraction. These parameters were measured three consecutive times and a mean value was considered. Two-dimensional images of 3 cardiac cycles were collected from three parasternal left ventricular short-axis sections, including the left ventricular mitral valve level, papillary muscle level, and apex level, and three left ventricular long-axis sections, including apex four-chamber heart, three-chamber heart, and two-chamber heart. The images were stored and analyzed offline. Image analysis was performed using EchoPac workstation (GE Healthcare USA): clear 2D images were selected, the time points of aortic valve opening and closing were determined using the Doppler flow spectrum, and then the above three left ventricular short-axis and left ventricular long-axis section of six aspects was selected. The endocardial surface of the 6 dynamic images of the section was manually drawn. The software drew the epicardial surface automatically, and the system automatically generated the longitudinal and circumferential strains for each layer. The region of interest was manually adjusted to ensure satisfactory tracking and the global longitudinal strain (GLS) of the left ventricle was recorded. An experienced researcher from the Echocardiology department performed the ultrasound examination and obtained the images of the patients, and another researcher, blinded to the basic information of the patients, analyzed the images to ensure the accuracy of the data.

Data collection
Demographic characteristics and underlying medical conditions were recorded systematically for each case. Clinical parameters, including sites of infection, the proportion of septic shock patients in those with sepsis, and chronic coexisting conditions were recorded.
The worst value of respiratory rate, blood pressure, heart rate, and body temperature within 24 h since the diagnosis of sepsis were recorded. Vasopressor dosing intensity (VDI) was the highest value within 24 h after the diagnosis of sepsis. The initial value of central venous pressure (CVP) after admission to ICU was recorded. The 24-h fluid balance, 24-h Sequential Organ Failure Assessment (SOFA), and Acute Physiology and Chronic Health Evaluation (APACHE II) score were recorded. LV GLS value, and the worst EF value in the first 72 h after enrollment were recorded. ICU mortality, in-hospital mortality, the rate of endotracheal intubation, the incidence of atrial fibrillation, the incidence of acute kidney injury (AKI), the proportion of patient with continuous renal replacement therapy (CRRT), the length of hospital stay, and the length of ICU stay were also recorded.

Statistical analysis
Statistical analyses were performed using the Stata software (v15.1; College Station, TX, USA). Normality tests were performed on continuous variables. Normally distributed measurement data were expressed as mean ± standard deviation. Inter-group comparisons were performed using an independent sample t-test. Non-normally distributed parameters were expressed as median (interquartile range) [M (IQR)]. Wilcoxon rank-sum test was used for comparison between groups and χ² test was used for comparison of measurement data between groups. Receiver operating characteristic (ROC) curves were drawn for parameters with significant differences between the two groups to identify the optimal cut-off value, and the results were converted to dichotomous variables according to the optimal cut-off value. Factors associated with left ventricular systolic dysfunction and mortality were analyzed using multivariate conditional logistic regression models. A backward stepwise logistic regression was performed to select variables for the multivariate models, using a cut-off p-value of 0.1. The goodness of fit was tested using the Hosmer–Lemeshow test. The risk factors were input into the R X643.6.3 statistical software by R Studio, and the "RMS" language package was used to draw a nomogram. New scores were developed to predict the risk of left ventricular systolic dysfunction for septic patients. Bootstrap was used for internal verification to calculate the C-index, to draw the correction curve of the nomogram, and to evaluate the consistency of the results. Kaplan–Meier method was used to draw the survival curve and the log-rank test was used to calculate the hazard ratio (HR). P<0.05 was considered statistically significant.

Results
Study population
From April 2020 to January 2021, a total of 177 patients were admitted to the department, of which, 41 patients were excluded (9 patients with severe arrhythmia, 1 pregnant patient, 2 patients with congenital heart disease, 5 patients with moderate-to-severe valvular heart disease or history of valve replacement, 5 patients with suspected acute myocardial infarction or myocarditis, 3 patients with end-stage cancer, and 16 patients with chronic heart failure). The remaining 136 patients were included in the study, of which, 12 patients were eliminated (5 patients did not complete echocardiography within 72 h, and the images of 7 patients were unclear and could not be analyzed using the EchoPac workstation). Therefore, data on 124 patients were finally considered for the analyses. The left ventricular systolic dysfunction group (LVSD group, LV GLS > −17%) included 51 patients (41.1%) and the non-left ventricular systolic dysfunction group (Non-LVSD group, LV GLS ≤ −17%) included 73 patients (58.9%) (Fig. 1).

Baseline characteristics and prognosis of the two groups
Comparison of baseline characteristics like age, gender, BMI, chronic coexisting conditions (hypertension, diabetes, chronic renal insufficiency, chronic respiratory failure), sites of infection, and proportion of patients with septic shock showed no significant differences between the groups (P>0.05) (Table 1). There were no significant
### Table 1  Demographic and clinical characteristics of patients with left ventricular systolic dysfunction and non-left ventricular systolic dysfunction

| Basic characteristic | Non-LVSD group \( (n = 73) \) | LVSD group \( (n = 51) \) | \( p \) |
|----------------------|-------------------------------|-----------------------------|------|
| Male sex—no. (%)     | 49 (67.1%)                    | 37 (72.5%)                  | 0.519|
| Age—year             | 68 (63.7, 69.4)               | 68 (57.7, 77.7)             | 0.931|
| BMI (kg/m²)          | 24.1 (21.6, 26.1)             | 22.5 (20.1, 25.2)           | 0.061|
| LV GLS (%)           | 17.6 (18.2, 19.6)             | 15.9 (14.7, 16.8)           | <0.001*|
| LV EF (%)            | 52.1 ± 0.5                    | 51.5 ± 0.8                  | 0.057|
| Septic shock—no. (%) | 54 (74.0%)                    | 39 (76.5%)                  | 0.752|
| Underlying medical conditions | | | |
| Hypertension—no. (%) | 33 (45.2%)                    | 25 (49.0%)                  | 0.675|
| Diabetes—no. (%)     | 14 (19.2%)                    | 8 (15.7%)                   | 0.616|
| Chronic kidney injury—no. (%) | 7 (9.6%) | 4 (7.8%) | 0.737|
| Clinical characteristics | | | |
| Respiratory rate (bpm) | 24 (20.29)                   | 22 (20.26)                  | 0.337|
| Blood pressure (mmHg) | 67.3 (60.7, 80)              | 73 (63.8, 85.7)             | 0.217|
| Heart rate (bpm)     | 110.3 ± 24.0                  | 112.0 ± 25.5                | 0.714|
| Body temperature (°C) | 37.8 ± 0.1                    | 37.6 ± 0.1                  | 0.476|
| CVP (mmHg)           | 8.4 ± 3.8                     | 9.9 ± 4.9                   | 0.087|
| Organ function score | | | |
| APACHE II score      | 16.0 (12.20)                  | 17 (14.22)                  | 0.352|
| SOFA score           | 9.6 ± 3.0                     | 10.9 ± 3.4                  | 0.027*|
| Laboratory data      | | | |
| Leucocyte count \( (10⁹/L) \) | 112 (62.1, 192)               | 99 (60.1, 175)              | 0.575|
| Hemoglobin (g/L)     | 108.0 ± 27.1                  | 105.3 ± 35.9                | 0.853|
| Platelet \( (10⁹/L) \) | 160 (104, 215)                | 134 (89, 224)               | 0.369|
| Albumin (g/L)        | 27.6 (23.7, 31.4)             | 29.7 (26.3, 32.8)           | 0.188|
| Bilirubin (mmol/L)   | 20.2 (12.5, 30.9)             | 18.8 (13.4, 25.8)           | 0.455|
| Plasma creatinine \( (umol/L) \) | 90.3 (62.8, 173.5)            | 110.2 (65.1, 178.9)         | 0.542|
| PCT (ng/mL)          | 3.3 (0.5, 21)                 | 22 (0.7, 91)                | 0.013|
| Hs-TnI (ng/mL)       | 0.04 (0.02, 0.12)             | 0.27 (0.07, 0.86)           | <0.001|
| NT-proBNP (pg/mL)    | 1020 (321, 3060)              | 4560 (1740, 9580)           | <0.001|
| pH                   | 7.34 ± 0.09                   | 7.32 ± 0.11                 | 0.337|
| Lac (mmol/L)         | 2.5 (1.7, 3.8)                | 3.7 (2.2, 5.9)              | 0.008|
| P(v-a)CO₂ > 6 mmHg no. (%) | 27 (61.4%) | 22 (64.7%) | 0.762|
| 24-h fluid balance (mL) | 1994.3 ± 159.6               | 1892.1 ± 237.9              | 0.711|
| Vasoactive drugs     | | | |
| VDI (ug/min)         | 18 (0.42)                     | 36 (12.60)                  | 0.007*|
| Inotropic drugs used—no. (%) | 2 (2.8%) | 4 (7.8%) | 0.193|
| Site of infection—no. (%) | | | |
| Lungs                | 20 (27.4%)                    | 20 (39.2%)                  | 0.196|
| Blood                | 1 (1.4%)                      | 2 (3.9%)                    | 0.096|
| Abdomen              | 45 (61.6%)                    | 21 (41.2%)                  | 0.196|
| Soft tissue          | 2 (2.7%)                      | 3 (5.9%)                    | 0.196|
| Urinary tract        | 2 (2.7%)                      | 2 (3.9%)                    | 0.196|
| Central nervous system | 2 (2.7%)                      | 0                           | 0.196|
| Others               | 1 (1.4%)                      | 3 (5.9%)                    | 0.196|

LVSD left ventricular systolic dysfunction, BMI body mass index, LV GLS left ventricular global longitudinal strain, LV EF left ventricular ejection fraction, SOFA Sequential Organ Failure Assessment, APACHE Acute Physiology and Chronic Health Evaluation, PCT procalcitonin, Hs-TnI high sensitive troponin I, NT-proBNP N-terminal pro-brain natriuretic peptide, Lac lactate, CVP central venous pressure, P(v-a)CO₂ venous-to-arterial carbon dioxide partial pressure difference, VDI vasopressor dosing intensity = [norepinephrine (ug/min)] + [dopamine (ug/kg/min) /2] + [epinephrine (ug/min)] + [phenylephrine (ug/min) /10] + [vasopressin (0.01 units/min) × 2]; \( * p < 0.05 \)
differences in the clinical parameters of respiratory rate, blood pressure, heart rate, body temperature, CVP, 24-h fluid balance, and APACHE II scores between the 2 groups ($P>0.05$). Also, there were no significant differences in the laboratory parameters of hemoglobin, white blood cell count, platelet count, bilirubin level, serum creatinine, pH, and proportion of arteriovenous CO$_2$ gap (P(V-A) CO$_2$ GAP) > 6 mm Hg between the two groups ($P>0.05$). However, Hs-TnI, PCT, Lac, NT-proBNP, SOFA, and VDI were significantly higher in the LVSD group compared to the Non-LVSD group ($P<0.05$) (Table 1). The ICU mortality, hospital mortality, and proportion of atrial fibrillation in the LVSD group were significantly higher than those in the Non-LVSD group ($P<0.05$) (Table 2). There were no significant differences in the proportion of tracheal intubation, AKI, and CRRT, length of ICU stay, and length of hospital stay between the two groups ($P>0.05$) (Table 2). There was no significant difference in EF between survivors and non-survivors [58% (54%, 60%) vs 55% (50%, 59%), $P=0.060$], but non-survivor patients had higher LV GLS [17.6% (16.8%, 18.6%) vs 16.8% (15.4%, 17.8%), $P=0.007$]. Kaplan–Meier survival analysis results showed that the 28-day mortality of patients with LVSD was significantly higher than that of Non-LVSD patients ($HR=3.104$, 95% CI = 1.617–5.957, $P<0.001$) (Fig. 2).

Table 2  Clinical outcomes of patients with left ventricular systolic dysfunction and non-left ventricular systolic dysfunction

| Outcomes                          | Non-LVSD group ($n=73$) | LVSD group ($n=51$) | p     |
|-----------------------------------|-------------------------|---------------------|-------|
| In-ICU mortality                  | 12(16.4%)               | 24(47.0%)           | <0.001|
| In-hospital mortality             | 14(19.2%)               | 25(49.0%)           | <0.001|
| Atrial fibrillation—no. (%)       | 6(8.2%)                 | 11(20.8%)           | 0.033 |
| Tracheal intubation—no. (%)       | 53(72.6%)               | 36(70.6%)           | 0.806 |
| AKI—no. (%)                       | 27(37.0%)               | 26(51%)             | 0.121 |
| CRRT—no. (%)                      | 21(28.8%)               | 18(35.3%)           | 0.441 |
| Median length of stay in ICU—days | 7(4,14)                 | 9(4,14)             | 0.811 |
| Median length of stay in hospital—days | 15(10,23)         | 14(7,18)            | 0.094 |

LVSD: left ventricular systolic dysfunction, AKI: acute kidney injury, CRRT: continuous renal replacement therapy

![Kaplan-Meier Estimates of Survival Function](image)

Fig. 2  Non-LVSD group and LVSD group on 28-day survival. The Kaplan–Meier method was used to estimate the probability of survival. In the adjusted analyses, there was significant difference between the two groups with respect to death at 28 days (hazard ratio was 3.104, 95% confidence interval [CI] 1.617 to 5.957). Results have not been adjusted for multiple comparisons. The shading indicates 95% confidence intervals. LVSD: left ventricular systolic dysfunction
Univariate analysis of risk factors for patients with LVSD

The diagnostic values of PCT, Hs-TnI, NT-proBNP, Lac, SOFA, and VDI for LVSD (Fig. 3) were compared. The area under the curve (AUC) of PCT in the diagnosis of LVSD was 0.631, the optimal cut-off value was 40 ng/mL, the sensitivity was 45.10%, the specificity was 83.56%, and the Youden index was 0.287. The AUC of Hs-TnI in the diagnosis of LVSD was 0.765, the optimal cut-off value was 0.131 ng/ml, the sensitivity was 68.63%, the specificity was 79.45%, and the Youden index was 0.481. The AUC of NT-proBNP in the diagnosis of LVSD was 0.726, the optimal cut-off value was 3270 pg/mL, the sensitivity was 58.8%, the specificity was 78.1%, and the Youden index was 0.369. The AUC of Lac in the diagnosis of LVSD was 0.641, the optimal cut-off value was 4.2 mmol/L, the sensitivity was 47.1%, the specificity was 84.9%, and the Youden index was 0.320. The AUC of SOFA in the diagnosis of LVSD was 0.643, the optimal cut-off value was 11, the sensitivity was 66.7%, the specificity was 63.0%, and the Youden index was 0.297. The ADI optimal cut-off value was 57 μg/min, the sensitivity was 48.1%, the specificity was 84.9%, and the Youden index was 0.261 (Table 3).

Multivariate analysis of risk factors for patients with LVSD

Multivariate logistic regression analysis showed that Hs-TnI $\geq 0.131$ ng/ml (OR = 6.71, 95% CI = 2.67 ~ 16.88, $P<0.001$), PCT $\geq 40$ ng/mL (OR = 3.08, 95% CI = 1.10 ~ 8.59, $P=0.032$), NT-proBNP $\geq 3270$ pg/mL (OR = 2.67, 95% CI = 1.06 ~ 6.74, $P=0.038$), and Lac $\geq 4.2$ mmol/L (OR = 2.80, 95% CI = 1.02 ~ 7.69, $P=0.045$) were significantly different. Hs-TnI $\geq 0.131$ ng/ml, PCT $\geq 40$ ng/mL, NT-proBNP $\geq 3270$ pg/mL, and Lac $\geq 4.2$ mmol/L were independent risk factors for LVSD (Table 4).

Establishment of a predictive model for patients with LVSD

Hs-TnI $\geq 0.131$ ng/ml, PCT $\geq 40$ ng/mL, NT-proBNP $\geq 3270$ pg/mL, and Lac $\geq 4.2$ mmol/L were included in the logistic regression model. Logistic regression model of $\ln(P/(1-P)) = -2.18 + [1.90 \text{Hs-TnI} (< 0.131 \text{ ng/ml} \text{ vs} \geq 0.131 \text{ ng/ml}, < 0.131 \text{ ng/ml} = 0, \geq 0.131 \text{ ng/ml} = 1)] + [1.12 \text{PCT} (< 40 \text{ ng/ml} \text{ vs} \geq 40 \text{ ng/ml}, < 40 \text{ ng/ml} = 0, \geq 40 \text{ ng/ml} = 1)] + [1.03 \text{Lac} (< 4.2 \text{ mmol/L} \text{ vs} \geq 4.2 \text{ mmol/L}, < 4.2 \text{ mmol/L} = 0, \geq 4.2 \text{ mmol/L} = 1)] + [0.98 \text{Nt-proBNP} (< 3270 \text{ pg/mL} \text{ vs} \geq 3270 \text{ pg/mL}, < 3270 \text{ pg/mL} = 0, \geq 3270 \text{ pg/mL} = 1)]$. The Hosmer–Lemeshow test was applied and the test results showed that
the model fit well ($P = 0.719$). The AUC of the predictive model was 0.839 ($P < 0.001$) (Fig. 4).

**Nomogram and verification**

According to logistic regression results, the four risk factors: PCT $\geq 40$ ng/ml, Hs-TnI $\geq 0.131$ ng/ml, NT-proBNP $\geq 3270$ pg/mL, and Lac $\geq 4.2$ mmol/L were used to draw the nomogram. The scores of the 4 factors were obtained: Hs-TnI $\geq 0.131$ ng/mL, 100 points; PCT $\geq 40$ ng/ml, 59 points; Lac $\geq 4.2$ mmol/L, 54 points; and NT-proBNP $\geq 3270$ pg/mL, 52 points (Fig. 5). The bootstrap test was used for internal verification. It was found that the correction curve was in good consistency with the ideal curve and the degree of calibration of the model was acceptable (Fig. 6). The C-index of the model was 0.822 (95% CI 0.750–0.894).

**Discussion**

Sepsis is the most common cause of death among critically ill patients. Globally, the mortality due to sepsis is about 10%, but that of septic shock can be as high as 40% [9, 10]. The heart is one of the main organs damaged due to sepsis, and sepsis patients may suffer from cardiac dysfunction due to immune disorders, oxidative stress, mitochondrial dysfunction, calcium overload, and other mechanisms [11]. A quarter of the deaths in septic shock patients are due to cardiac dysfunction [12]. Establishing an early predictive model may be helpful for the diagnosis and treatment of sepsis-related cardiac dysfunction (SRCD). More and more indicators that may be related to SRCD have been reported [13]. NT-proBNP and Hs-TnI are cardiac tissue damage biomarkers. Sepsis patients often show increased NT-proBNP and Hs-TnI, which is significantly related to the increased risk of death of patients [14, 15], but damaged heart function in sepsis is often associated with a variety of factors (the weight of each factor may be inconsistent); therefore, a comprehensive prediction model may be more valuable than a single factor. Our study showed that patients with LVSD had higher Hs-TnI, PCT, NT-proBNP, Lac, SOFA, and VDI. Moreover, Hs-TnI $\geq 0.131$ ng/ml, PCT $\geq 40$ ng/ml, Lac $\geq 4.2$ mmol/L, NT-proBNP $\geq 3270$ pg/mL, SOFA $\geq 11$, and VDI $\geq 57$ μg/min had high specificity in the diagnosis of LVSD. Hs-TnI $\geq 0.131$ ng/ml, PCT $\geq 40$ ng/ml, Lac $\geq 4.2$ mmol/L, and NT-proBNP $\geq 3270$ pg/mL were independent risk factors for LVSD, and the accuracy and discrimination of the predictive model were acceptable. According to the four risk factors of LVSD in the nomogram, scores can be easily calculated, and the probability of sepsis patients complicated with cardiomyopathy can be calculated using the score.

**Table 3** Diagnostic performance of PCT, Hs-TnI, NT-proBNP, Lac and SOFA for left ventricular systolic dysfunction in patients with sepsis

| Variable  | AUC  | Optimal cut-off value | Sensitivity (%) | Specificity (%) | 95% CI Upper limit | Lower limit | Yoden index | p            |
|-----------|------|-----------------------|----------------|----------------|-------------------|------------|-------------|--------------|
| PCT       | 0.631| 40                    | 45.1           | 83.6           | 0.528             | 0.733      | 0.287       | 0.013        |
| Hs-TnI    | 0.765| 0.131                 | 68.6           | 79.5           | 0.675             | 0.856      | 0.481       | <0.001       |
| NT-proBNP | 0.726| 3270                  | 58.8           | 78.1           | 0.637             | 0.815      | 0.369       | <0.001       |
| Lac       | 0.641| 4.2                   | 47.1           | 84.9           | 0.540             | 0.741      | 0.320       | 0.006        |
| SOFA      | 0.643| 11                    | 66.7           | 63.0           | 0.541             | 0.746      | 0.297       | 0.006        |
| VDI       | 0.641| 57                    | 41.2           | 84.9           | 0.541             | 0.741      | 0.261       | 0.006        |

PCT: procalcitonin, Hs-TnI: high sensitive troponin I, NT-proBNP: N-terminal pro-brain natriuretic peptide, Lac: lactate, SOFA: Sequential Organ Failure Assessment, VDI: vasopressor dosing intensity = [norepinephrine (ug/min)] + [dopamine (ug/kg/min) /2] + [epinephrine (ug/min)] + [phenylephrine (ug/min) /10] + [vasopressin (0.01 units/min) × 2]. AUC: area under the curve, 95%CI: 95% confidence interval.

**Table 4** Multivariate logistic regression analysis for predictors of patients with left ventricular systolic dysfunction

| Variable | Coef. | SE  | z    | p    | OR  | 95% CI Upper limit | Lower limit |
|----------|-------|-----|------|------|-----|--------------------|-------------|
| PCT $> 40$ ng/ml | 1.12  | 0.52 | 2.15 | 0.03 | 3.08 | 1.10               | 8.59        |
| Hs-TnI $\geq 0.131$ ng/ml | 1.90  | 0.47 | 4.04 | <0.001 | 6.71 | 2.67               | 16.88       |
| NT-proBNP $\geq 3270$ pg/ml | 0.98  | 0.47 | 2.08 | 0.04 | 2.67 | 1.06               | 6.74        |
| Lac $\geq 4.2$ mmol/L | 1.03  | 0.51 | 2.00 | 0.05 | 2.80 | 1.02               | 7.69        |

Coef.: regression coefficient, SE: standard error, OR: odds ratio, 95% CI: 95% confidence interval, PCT: procalcitonin, Hs-TnI: high sensitive troponin I, NT-proBNP: N-terminal pro-brain natriuretic peptide, Lac: lactate, SOFA: Sequential Organ Failure Assessment.
Fig. 4  Receiver operating characteristic curves showing the predictions of the model for left ventricular systolic dysfunction in patients with sepsis.

AUC = 0.839, 95%CI = 0.766 - 0.910, p < 0.001

Fig. 5  Individualized predictive nomogram model in diagnosing the left ventricular systolic dysfunction in sepsis patients. PCT procalcitonin, Hs-TnI high sensitive troponin I, NT-proBNP N-terminal pro-brain natriuretic peptide, Lac lactate.
The increase in cardiac troponin I (cTnI) is the most important warning signal for LVSD. cTnI is the only TnI isoform in human myocardial fibers and a specific marker of myocardial injury [16]. It is released early upon myocardial cell injury. As early as 2011, Røsjø et al. reported that elevated troponin levels in patients with sepsis were associated with poor prognosis [17]. Kim et al. reported that the peak concentration of Hs-TnI in septic patients with cardiac dysfunction was significantly higher than that in patients without cardiac dysfunction, and the peak concentration in the subgroup of patients with systolic dysfunction was higher than that in patients without systolic dysfunction [18]. Our study excluded 5 patients who may have acute myocardial infarction and myocarditis. It was also found that elevated Hs-TnI was significantly related to LVSD. Therefore, LVSD should be considered in patients with sepsis who show no other reason for the elevation in troponin I.

Inflammation is an important mechanism of organ damage in patients with sepsis. PCT has a good correlation with the degree of inflammation in patients [19]. Our study found that PCT in patients with LVSD is higher than that in patients with non-LVSD. PCT ≥ 40 ng/ml was an independent risk factor for LVSD, indicating that excessive inflammation may cause cardiomyocyte damage. Lactic acid is the product of tissue anaerobic glycolysis. Our study showed Lac > 4.2 mmol/L was a risk factor for LVSD. The increased Lac indicated that tissue may have suffered hypoperfusion, myocardial tissue may also have lacked perfusion. The myocardial mitochondria are damaged due to insufficient perfusion, which in turn leads to a decline in myocardial function. In addition, local metabolic acidosis may inhibit heart function directly. Innocenti et al. reported that patients with sepsis and septic shock with Lac ≥ 2 mmol/L have lower absolute values of LV GLS than patients with Lac < 2 mmol/L [20]. Our study showed similar results.

N-terminal pro-brain natriuretic peptide (NT-proBNP) is an inactive N-terminal fragment of brain natriuretic peptide (BNP). Its secretion increases with the increase in ventricular pressure and ventricular wall tension, which is an important indicator of cardiac insufficiency, and the higher the concentration, the more accurate is the diagnosis of cardiac insufficiency [21]. In 2004, Charpentier et al. reported a relationship between BNP and ejection fraction in 34 patients with sepsis and found that 15 patients with sepsis showed a decreased ejection fraction (EF < 50%), and BNP in patients with a decreased ejection fraction was significantly higher than that in patients with normal ejection fraction. Also, it was proposed that

![Fig. 6 Calibration curves for the prediction of left ventricular systolic dysfunction in patients with sepsis by the nomogram](image-url)
BNP can be used for the detection of cardiac function in patients with sepsis [22]. Later, it was found that the increase in BNP in patients with sepsis was correlated more strongly with the patient’s condition. Even if the ejection fraction was normal, the BNP in patients with a poor prognosis was elevated, suggesting that ejection fraction cannot sensitively and accurately reflect the cardiac dysfunction of patients with sepsis [23]. However, when LV GLS was used to diagnose left ventricular systolic dysfunction in patients with sepsis, BNP was more strongly correlated with the patient’s prognosis [24]. Our study showed similar results. Patients with LVSD have higher NT-proBNP, suggesting that it can be used as one of the parameters of the predictive model for LVSD based on the diagnosis using LV GLS. However, the score of elevated NT-proBNP was the lowest among the four parameters, which may be related to the detection time. Usually, it takes more time for the compensatory secretion of BNP by the cardiomyocytes to increase after the ventricular pressure increases [25].

Our study, however, had several limitations: (1) SRCD can be categorized into left ventricular systolic and diastolic dysfunction, right ventricular systolic and diastolic dysfunction [26]. LV GLS reflects only the left ventricular systolic function, and left ventricular diastolic function and right ventricular dysfunction were not measured. An increasing number of reports suggested that sepsis-related right ventricular dysfunction is more important in SRCD and associated with the prognosis of patients. (2) GLS measurement needs to be performed by doctors specializing in ultrasound, and it is affected by different parameters, which may be related to the detection time. Usually, it takes more time for the compensatory secretion of BNP by the cardiomyocytes to increase after the ventricular pressure increases [25].

Our study showed similar results. Patients with LVSD have higher NT-proBNP, suggesting that it can be used as one of the parameters of the predictive model for LVSD based on the diagnosis using LV GLS. However, the score of elevated NT-proBNP was the lowest among the four parameters, which may be related to the detection time. Usually, it takes more time for the compensatory secretion of BNP by the cardiomyocytes to increase after the ventricular pressure increases [25].

**Conclusion**

Our study showed that Hs-TnI $\geq 0.131$ ng/ml, PCT $\geq 40$ ng/ml, Lac $\geq 4.2$ mmol/L, and NT-proBNP $\geq 3270$ pg/ml are independent risk factors for left ventricular systolic dysfunction in patients with sepsis and the predictive model is acceptable. Patients with LVSD have a higher risk of death and atrial fibrillation than sepsis patients with normal cardiac function.

**Abbreviations**

LV GLS: Left ventricular global longitudinal strain; LVSD: Left ventricular systolic dysfunction; SRCD: Sepsis-related cardiac dysfunction; AKI: Acute kidney injury; PCT: Procalcitonin; Lac: Lactate; NT-proBNP: N-terminal pro-brain natriuretic peptide; LVEF: Left ventricular ejection fraction; GLS: Global longitudinal strain; CVP: Central venous pressure; VDI: Vasopressor dosing intensity; SOFA: Sequential Organ Failure Assessment; APACHE II: Acute Physiology and Chronic Health Evaluation II; CRRT: Continuous renal replacement therapy; M (IQR): Median (inter-quartile range); ROC: Receiver operating characteristic; HR: Hazard ratio; P(V-A) CO2 GAP: Arteriovenous CO2 gap; AUC: Area under the curve; CI: Confidence interval; ICU: Intensive care unit.

**Acknowledgements**

The authors would like to thank all the reviewers who participated in the review and MJElder (www.mjeeditor.com) for its linguistic assistance during the preparation of this manuscript. Sincere appreciation is expressed to Dr. Jing Yuan and Dr. Yong Chen for their assistance in ultrasound examination.

**Author contributions**

DW developed the study protocol and conducted the initial search for studies. JY drafted the manuscript. PY included patients and formed the statistical analyses. RZ critically reviewed the manuscript. All authors read and approved the final manuscript.

**Funding**

This work was supported by Yangzhou Medical Talent (ZDRC201845), Top-notch Talents of “Six-one Projects” of Jiangsu Commission of Health (LGY2019036), and Jiangsu Province “333 Projects” (BRA2020183), Northern Jiangsu People’s Hospital Support Project (fcjs202024).

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The protocol was registered with the Chinese Clinical Trial Registry (No: ChiCTR2000032128) on 20 April 2020, http://www.chictr.org.cn/showproj.aspx?proj=52531, and approved by the Ethical Committee of the Northern Jiangsu People’s Hospital (ky2020007). All patients gave informed consent.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they do not have any competing interests.

**Author details**

1 Medical College, Yangzhou University, Yangzhou 225001, China. 2 Intensive Care Unit, Northern Jiangsu People’s Hospital, Yangzhou 225001, China. 3 Intensive Care Unit, Jiangdu People’s Hospital, Yangzhou 225299, China.

Received: 11 March 2022 Accepted: 3 June 2022 Published online: 15 June 2022

**References**

1. Weisel RD, Vito L, Dennis RC, Valeri CR, Hechtman HB. Myocardial depression during sepsis. Am J Surg. 1977;133(4):512–21.

2. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1984;100(4):483–90.
3. Antonucci E, Agosta S. Speckle tracking echocardiography: another step towards early detection of septic myocardial dysfunction? Crit Care. 2016;20(1):236–7.

4. Ehrman RR, Sullivan AN, Favot MJ, Shenwin RL, Reynolds CA, Abidov A, et al. Pathophysiology, echocardiographic evaluation, biomarker findings, and prognostic implications of septic cardiomyopathy: a review of the literature. Crit Care. 2018;22(1):112–25.

5. Chang WT, Lee WH, Lee WT, Chen PS, Su YR, Liu PY, et al. Left ventricular global longitudinal strain is independently associated with mortality in septic shock patients. Intensive Care Med. 2015;41(10):1791–9.

6. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock. 2016. Intensive Care Med. 2017;43(3):304–77.

7. Yuan J, Chen M, Chen S, Hu C, Cai G, Yan J. Effect of left ventricular global longitudinal strain on prognosis of septic/septic shock patients: a meta-analysis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018;30(9):842–7.

8. Xie J, Wang H, Kang Y, Zhou L, Liu Z, Qin B, et al. The epidemiology of sepsis in Chinese ICUs: a national cross-sectional survey. Crit Care Med. 2020;48(3):e209–18.

9. Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefl J, Adam D. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019—results from a systematic review and meta-analysis. Crit Care. 2020; 24(1).

10. Singer M, Deutschman CS, Seymour CW, Videtic GK, Dhainaut J, Annane D, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.

11. Kakihana Y, Ito T, Nakahara M, Yamaguchi K, Yasuda T. Sepsis-induced myocardial dysfunction: pathophysiology and management. J Intensive Care. 2016;4:22.

12. Walker AMN, Drozd M, Hall M, Patel PA, Paton M, Lowry J, et al. Prevalence and predictors of sepsis death in patients with chronic heart failure and reduced left ventricular ejection fraction. J Am Heart Assoc. 2018;7(20):e009684.

13. Beesley SJ, Weber G, Sarge T, Nikravan S, Grissom CK, Lanspa MJ, et al. Septic cardiomyopathy. Crit Care Med. 2018;46(4):625–34.

14. van Beek D, van Zaane B, Looije M, Peelen L, van Klei W. Typical rise and fall of troponin in (peri-procedural) myocardial infarction: a systematic review. World J Cardiol. 2016;8(3):293–301.

15. Klouche K, Pommet S, Amigues L, Bargnoux AS, Dupuy AM, Machado S, et al. Plasma brain natriuretic peptide and troponin levels in severe sepsis and septic shock: relationships with systolic myocardial dysfunction and intensive care unit mortality. J Intensive Care Med. 2014;29(4):229–37.

16. Babuin L, Vasile VC, Perez JA, Alegria JR, Chai HS, Afessa B, et al. Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients. Crit Care Med. 2008;36(3):759–65.

17. Røsjø H, Varpula M, Hagve TA, Karlsson S, Ruokonen E, Pettilä V, et al. Septic cardiomyopathy. Crit Care. 2018;22(1):112–25.

18. Kim JS, Kim M, Kim YJ, Ryoo SM, Sohn CH, Ahn S, et al. Troponin testing for assessing sepsis-induced myocardial dysfunction in patients with septic shock. J Clin Med. 2019;8(2):239–51.

19. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36(3):941–52.

20. Innocenti F, Palmieri V, Stefanone VT, D’Argenzio F, Cigana M, Montuori M, et al. Prognostic stratification in septic patients with overt and cryptic shock by speckle tracking echocardiography. Intern Emerg Med. 2021;16(3):757–64.

21. Hall C. NT-ProBNP: the mechanism behind the marker. J Cardiac Fail. 2005;11(5):581–3.

22. Charpentier J, Luyt CE, Filla Y, Vinsonneau C, Cariou A, Grabar S, et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med. 2004;32(3):660–5.

23. Pandompintam G, Kashani K, Vallabhajosyula S. The role of natriuretic peptides in the management, outcomes and prognosis of sepsis and septic shock. Rev Bras Ter Intensiva. 2019;31(3):368–78.

24. Dalla K, Hallman C, Beck-Hanssen O, Haney M, Ricksten SE. Strain echocardiography identifies impaired longitudinal systolic function in patients with septic shock and preserved ejection fraction. Cardiovasc Ultrasound. 2015;13:30–9.

25. Ng TMH, Yeung SL. Is there an optimal time or method to obtain BNP levels? J Card Fail. 2019;25(9):722–4.

26. Wang J, Wang XT, Liu DW, Zhang HM, Su LX. Induction and deduction in sepsis-induced cardiomyopathy: five typical categories. Chin Med J (Engl). 2020;133(18):2205–11.